(2007) found that intranasally administered epithalon significantly activated neuron activity in the cerebral cortex of white rats, presenting findings that the peptide may be of interest in clinical applications for the treatment of CNS activity impairments [9]
Once activated, AMPK initiates a cascade of events that promote ATP production and inhibit ATP-consuming processes
At the same time, the FDAs back-and-forth stance on NMN first banning it in 2022, then allowing it again in 2025 added more fuel to the confusion
Scientific Support From Preclinical Studies Research on BPC-157, TB-500, and their potential biological roles is based primarily on animal studies, cell-culture experiments, and early-stage preclinical investigations
A medRxiv preprint posted April 13, 2026 (nference + Mayo Clinic) used EHR-linked digital phenotyping on 670,422 first-episode GLP-1 users to compare body-composition trajectories on tirzepatide versus semaglutide in routine clinical care